| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3395 |
| Trial ID | NCT05801913 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | CMV-modified vaccinia Ankara |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 22459|NCI-2023-02195|22459|P30CA033572 |
| Cohort 1 | |||||||||||
|
|||||||||||